乙型肝炎病毒（HepatitisBVirus，HBV）感染是中国乃至全球重要的公共卫生问题。全球近2.4亿人为慢性乙肝病毒携带者，每年约65万人死于肝硬化、肝癌等HBV感染相关疾病（WHO）。现有的抗病毒治疗尚不能根治乙肝，接种预防性乙肝疫苗是预防HBV感染，降低人群HBsAg(HepatitisBSurfaceAntigen)携带率最为有效的手段。注射疫苗后的个体会产生不同的抗体水平，不同的抗体中和活性将决定宿主对于HBV的保护性。有研究显示，约有10-15%的人群在接种疫苗后无应答或低应答，可能需要加大接种剂量。目前主要评价中和抗体活性的方法主要是基于“结合活性”的免疫化学分析法，如酶联免...Hepatitis B virus infection is an important public health problem in China and around the world. About 2 billion people worldwide have been infected with HBV, and more than 400 million people are chronic hepatitis B virus carriers. Each year about 650,000 people died of liver cirrhosis, liver cancer and other HBV infection related diseases. However, the current antiviral therapy can only induce di...学位：医学硕士院系专业：公共卫生学院_转化医学学号：3262014115057
